FibroGen $FGEN backtracked on some of the key safety data used to boost hopes for their anemia drug roxadustat, eliminating its claim of superiority over ESAs for a large segment of the patient population. And investors quickly crushed its shares in retaliation for the surprise discrepancies. According to CEO Enrique Conterno, FibroGen execs became “aware” … Continue reading FibroGen shares take a beating as CEO reveals safety data manipulation for its blockbuster contender roxadustat